Drug Search Results
More Filters [+]

Imidafenacin

Alternative Names: imidafenacin, ono-8025, ono8025, ono 8025
Latest Update: 2024-04-19
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: M1 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Chile | Ecuador | Egypt | Indonesia | Japan | Malaysia | Mexico | Philippines | Russia | Taiwan

Approved Indications: None

Known Adverse Events: None

Company: ONO Pharm
Company Location: CHUO-KU OSAKA 541 JA M0
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Imidafenacin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Overactive Bladder

Phase 2: Chronic Obstructive Pulmonary Disease|Overactive Bladder

Phase 1: Urinary Incontinence, Urge|Overactive Bladder

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

178-MA-3146

N/A

Completed

Overactive Bladder

2020-03-30

CTR20191280

N/A

Completed

Urinary Incontinence, Urge

2019-09-17

178-MA-3147

N/A

Completed

Overactive Bladder

2019-09-13

CTR20191340

N/A

Completed

Urinary Incontinence, Urge

2019-09-04

Recent News Events